ArticleJournal of ophthalmology2026
Associations Between Baseline Biomarkers and Functional Outcomes in Patients With Diabetic Macular Edema After Anti-VEGF Treatment.
Article in Journal of ophthalmology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: To investigate associations between baseline structural and functional biomarkers and 6-month post-treatment best-corrected visual acuity (BCVA) among patients with diabetic macular edema (DME) receiving intravitreal anti-VEGF therapy. Methods: Data from patients treated at Hebei Eye Hospital between December 2022 and January 2024 were retrospectively analyzed. Baseline biomarkers, including the disruption of the external limiting membrane (ELM) and ellipsoid zone (EZ), disorganization of retinal inner layers (DRIL), and epiretinal membrane (ERM) on spectral domain optical coherence tomography (SD-OCT), as well as the amplitude and implicit time of N1 and P1 waves in multifocal electroretinography (mfERG), were collected. The associations between these biomarkers and BCVA after anti-VEGF treatment were then assessed. Linear regression analysis was applied to quantify the correlations between baseline SD-OCT morphological biomarkers and 6-month anti-VEGF visual therapeutic efficacy. Multivariate logistic regression analysis was conducted to assess the efficacy of anti-VEGF treatment and baseline mfERG biomarkers. Results: A total of 87 eligible DME patients completed three monthly anti-VEGF loading injections and 6-month follow-up, including 48 patients in the response group and 39 in the nonresponse group. Linear regression assessed whether baseline retinal layer disruption predicted 6-month visual response and revealed that extensive ELM ( Conclusions: Baseline SD-OCT and mfERG biomarkers were significantly associated with anti-VEGF treatment outcomes in this DME cohort. Shorter N1 and P1 implicit times in the first and second mfERG rings were correlated with favorable treatment responses, while extensive disruption of ELM and EZ, severe DRIL, and the presence of tractional ERM were linked to poorer anti-VEGF responses. These structural and functional biomarkers may offer potential prognostic reference value for evaluating treatment prognosis. Further large-sample and prospective studies are still required to validate their clinical applicability and routine use in guiding therapeutic decision-making.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.